JBF Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

JBF Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,139	Closed	-$46K	–	95
2014 Q1	$46K	Buy	+1,139	New	+$41.4K	0.01%	78

Other funds holding ENTA

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Insight Capital Research & Management Walnut Creek, California $177M AUM 72% 1-Year Est. Return

JBF Capital's ENTA Position: Q2 2014 in Review

JBF Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2014, closing a stake of 1,139 shares — an estimated $46K sold.

JBF Capital first reported a position in ENTA in Q1 2014 and held it in 1 quarter. The position peaked at $46K in Q1 2014. 98 funds tracked by Wall St. Rank hold ENTA as of Q2 2014.

JBF Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
JBF Capital sold 1,139 Enanta Pharmaceuticals shares in Q2 2014, an estimated $46K.
JBF Capital first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 1 quarter.
JBF Capital's Enanta Pharmaceuticals position peaked at $46K in Q1 2014.
98 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2014.

Based on JBF Capital's 13F filing for Q2 2014, filed 13 Aug 2014.